Clinical trials
Alzheimer's Disease Dementia clinical trials
Below are recruiting alzheimer's disease dementia clinical trials, each written for real people, not researchers. We’re tracking 471 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT00064870Recruiting
Alzheimer's Disease Family Genetics Study
This study collects biological samples (blood or cells) from families where two or more members have been diagnosed with Alzheimer's disease or dementia. Researchers use these samples to identify genetic factors that may cause or increase risk for these conditions.
Nationwide, IndianaAges 18 years+ - NCT03082755RecruitingPhase 4
Study sleep agitation and restless legs in Alzheimer’s patients
This trial studies treatment for troubling nighttime restlessness and agitation in people with Alzheimer’s disease. It may help improve sleep and nighttime comfort and reduce nighttime behavior problems.
Austin, TexasAges 55 years+ - NCT07857759Recruiting
Neck lymph node surgery for early Alzheimer's disease
This study tests whether a microsurgery on lymph nodes in the neck can help clear waste from the brain in people with early Alzheimer's. It might slow down memory loss.
GdanskAges 18 years+ - NCT06442852Recruiting
Blood microRNA linked to Alzheimer's risk and severity
This study looks for tiny molecules (miRNAs) in your blood that might be linked to Alzheimer's disease risk and severity. It compares people with Alzheimer's to healthy volunteers to find potential early warning signs.
Wuhan, HubeiAges 65 years+ - NCT07787169RecruitingPhase 1
Study of amyloid-targeting therapies for Alzheimer's disease
This study tests several new experimental medications that target amyloid plaques, the protein clumps linked to Alzheimer's disease. It aims to find out if these treatments are safe and well-tolerated in people with early-stage Alzheimer's and in healthy volunteers.
Anaheim, CaliforniaAges 18–85 - NCT06567431Recruiting
Blood and tears in alzheimer's disease
This study looks at different fluids from the body, like blood and tears, to find better ways to diagnose and track alzheimer's and related dementias. It compares people with these conditions to healthy volunteers to see what biological markers differ.
CopenhagenAges 30 years+ - NCT07598370RecruitingPhase 1
Testing LY3439539 for early-stage Alzheimer's disease
This study tests an experimental drug called LY3439539 in people with early-stage Alzheimer's disease. The drug is designed to target protein changes in the brain that may slow memory loss and cognitive decline.
Irvine, CaliforniaAges 50–85 - NCT07571161RecruitingPhase 3
Donanemab for early Alzheimer's disease in Chinese participants
This trial tests a drug called donanemab in people who have early signs of Alzheimer's disease (amyloid buildup in the brain) but are still thinking clearly. The goal is to see if the drug can slow or prevent cognitive decline before memory problems start.
BeijingAges 55–80 - NCT06732128Recruiting
Nature virtual reality for depression in Alzheimer's disease
This trial tests whether a virtual reality nature experience can help improve mood in people with early-to-moderate Alzheimer's disease. Participants will use a VR headset and a few apps at home, with a caregiver present, over several sessions.
Toronto, OntarioAges 50 years+ - NCT07543094Enrolling by invitation
Brain Stimulation for Early Alzheimer's Memory and Thinking
This study tests whether a special type of brain stimulation called temporal interference stimulation can improve memory and thinking skills in people with early-stage Alzheimer's disease. The treatment uses electrical stimulation to target specific brain areas without surgery.
Shanghai, Shanghai MunicipalityAges 50–75 - NCT05801380Recruiting
Tracking how well a medicine works in Alzheimer’s patients
This study looks at how effective a treatment is in people newly diagnosed with mild to moderate Alzheimer’s disease. It also involves health and medication history checks and likely stool (fecal) sample collection to monitor effects.
Manila, National Capital RegionAges 65 years+ - NCT06535308RecruitingPhase 1
Testing a new Alzheimer's drug for moderate disease
This study tests a new drug (BnH-015B) for people with moderate Alzheimer's disease. It also includes a small group of healthy young men for comparison. The goal is to see if the drug is safe and how it works in the body.
Seoul, Jongno-guAges 19–45 - NCT06702124RecruitingPhase 3
Rotigotine patch with rivastigmine for mild to moderate Alzheimer's
This trial tests if adding a rotigotine patch to your usual rivastigmine treatment can help with symptoms of Alzheimer's. It is for people with mild to moderate Alzheimer's who have been stable on rivastigmine for at least 3 months.
Rome, ItalyAges 50–85 - NCT06837272Recruiting
Gut health and brain health in Alzheimer's disease
This study looks at how the bacteria in your gut might be connected to memory and thinking problems in Alzheimer's disease. It may help us understand if changes in the gut can affect brain health.
Jining, ShandongAges 60–80 - NCT05413655RecruitingPhase 2
Oral drug for mild Alzheimer’s disease symptoms
This Phase 2 trial tests an oral medicine (EX039) to see if it can help people with mild Alzheimer’s disease. It focuses on slowing or improving thinking and memory problems over time.
TaipeiAges 50–80 - NCT07328451RecruitingPhase 1
Study of DNL628 for people with early Alzheimer's disease
This trial tests an experimental drug, DNL628, to see if it is safe and how it affects people with early Alzheimer's disease. It may help slow the disease by targeting a specific process in the brain.
's-HertogenboschAges 18–75 - NCT07323927RecruitingEarly Phase 1
Testing galcanezumab for Alzheimer's disease
This trial tests whether galcanezumab, an antibody injection, can help people with mild-to-moderate Alzheimer's disease. It is for patients who have a confirmed Alzheimer's diagnosis and a caregiver who can support them.
BeijingAges 50–90 - NCT06874231Recruiting
Brain connectivity marker for Alzheimer's disease
This study uses brain scans to find a marker for Alzheimer's disease. It is looking for people with normal memory, mild memory problems, or mild Alzheimer's, and who can undergo a spinal tap and MRI.
Stockholm, SolnaAges 40–85 - NCT07294885Recruiting
Lymphatic surgery for Alzheimer's disease
This study tests a surgical procedure to connect lymph vessels in the neck to veins, which may help clear waste from the brain in people with mild cognitive impairment or mild to moderate Alzheimer's disease. It is for patients who have not improved after at least 3 months of standard care.
ShenyangAges 50–80 - NCT06883019Recruiting
Lecanemab for early onset inherited Alzheimer's
This trial tests a medication called lecanemab for people with early onset familial Alzheimer's disease. It aims to see if the drug can help slow cognitive decline in those with confirmed signs of Alzheimer's in their brain.
Beijing, ChinaAges 18–65 - NCT07213349RecruitingPhase 2
Daridorexant for Alzheimer's prevention
This study tests whether daridorexant, a medication that helps improve sleep, can prevent Alzheimer's disease. If you have mild memory concerns but not dementia, this trial may help find out if better sleep can protect your brain.
Montreal, QuebecAges 50–90 - NCT07208344RecruitingEarly Phase 1
Umbilical cord blood infusion for Alzheimer's disease
This early-phase study tests whether infusing donated umbilical cord blood (a source of young immune cells) can help slow Alzheimer's disease. It is for people aged 50–75 with mild to moderate Alzheimer's who have a caregiver and are otherwise generally healthy.
Hefei, AnhuiAges 50–75 - NCT06936124Recruiting
Deep brain stimulation for Alzheimer's disease
This trial tests whether deep brain stimulation of a specific brain area can help people with Alzheimer's disease. It aims to see if this treatment can improve symptoms and quality of life.
Toronto, OntarioAges 60 years+ - NCT07153848Recruiting
Lecanemab treatment for early Alzheimer's disease
This study tests how lecanemab works in people with early Alzheimer’s, including those with mild dementia or mild memory problems. It aims to see if the drug can help clear brain plaques and slow down symptoms.
Hangzhou, ZhejiangAges 45–85
Hear when a new Alzheimer's Disease Dementia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for alzheimer's disease dementia?
- Yes. Clin2 currently lists 471 recruiting alzheimer's disease dementia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a alzheimer's disease dementia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a alzheimer's disease dementia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.